Table 1e.

Subjective symptoms and other measurements of studies with a follow-up period of minimum 12 months

Publication	Symptoms	ETDQ-7	Other
Silvola et al., 2014 [8]	Improvement: 90%	NR	Mean mucosal inflammation score 2.8 → 1.4 (scale 1–4), p<0.0001
Schröder et al., 2015 [10]	At 2 year 89 patients (154 ears), 34% responded: no complaints: 47% improvement: 26% no improvement: 27%	NR	At 2 year: 60% satisfied 20% completely satisfied only for the first few months 20% dissatisfied
Dalchow et al., 2016 [9]	NR	NR	NR
Xiong et al., 2016 [11]	Overall reduced in 98%; Aural fullness disappeared in 83%; Aural fullness 8.2 (VAS 1–10 scale) → 1.3, p<0.05 Muffled hearing (VAS) 6.7 → 1.5, p<0.05 Otalgia (VAS) 5.2 → 1.9, p<0.05 Tinnitus (VAS) 4.4 → 2.2, p<0.05	NR	NR
Leichtle et al., 2017 2	Pressure in the ear: always: 59% → 4% mostly: 24% → 6%* sometimes: 6% → 10%* rarely: 5% → 48%* never: 5% → 31%* Subjective hearing loss: severe: 18% → 4% moderate: 19% → 4%* low-grade: 26% → 20%* slight: 21% → 35%* no: 16% → 37% Otalgia: always: 5% → 5%* mostly: 16% → 5%* sometimes: 18% → 16%* rarely: 29% → 37%* never: 31% → 37%*	NR	Limitation in daily life: severe: 25% → 5% moderate: 35% → 13% low-grade: 23% → 11% no: 6% → 46% Totally or moderately satisfied: 73%

p-values taken from publication if given.

^*, numbers estimated from a figure. ETDQ-7, Eustachian Tube Dysfunction Questionnaire; NR, not reported; VAS = Visual Analog Scale.